Our top pick for
Organovo Holdings, Inc is a diagnostics & research business based in the US. Organovo shares (ONVO) are listed on the NASDAQ and all prices are listed in US Dollars. Organovo employs 6 staff and has a trailing 12-month revenue of around USD$1.5 million.
|Latest market close||USD$10.28|
|52-week range||USD$0.1933 - USD$13.6|
|50-day moving average||USD$7.7809|
|200-day moving average||USD$10.3752|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.214|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-19.56%|
|1 month (2020-12-16)||41.40%|
|3 months (2020-10-16)||6.42%|
|6 months (2020-07-16)||1,531.75%|
|1 year (2020-01-16)||2,135.75%|
|2 years (2019-01-16)||817.86%|
|3 years (2018-01-16)||655.88%|
|5 years (2016-01-15)||446.81%|
|Revenue TTM||USD$1.5 million|
|Gross profit TTM||USD$-3,416,000|
|Return on assets TTM||-21.74%|
|Return on equity TTM||-49.75%|
|Market capitalisation||USD$55.2 million|
TTM: trailing 12 months
There are currently 145,381 Organovo shares held short by investors – that's known as Organovo's "short interest". This figure is 44.9% up from 100,329 last month.
There are a few different ways that this level of interest in shorting Organovo shares can be evaluated.
Organovo's "short interest ratio" (SIR) is the quantity of Organovo shares currently shorted divided by the average quantity of Organovo shares traded daily (recently around 106897.79411765). Organovo's SIR currently stands at 1.36. In other words for every 100,000 Organovo shares traded daily on the market, roughly 1360 shares are currently held short.
However Organovo's short interest can also be evaluated against the total number of Organovo shares, or, against the total number of tradable Organovo shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Organovo's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Organovo shares in existence, roughly 20 shares are currently held short) or 0.0286% of the tradable shares (for every 100,000 tradable Organovo shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Organovo.
Find out more about how you can short Organovo stock.
We're not expecting Organovo to pay a dividend over the next 12 months.
Organovo's shares were split on a 1:20 basis on 19 August 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Organovo shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Organovo shares which in turn could have impacted Organovo's share price.
Over the last 12 months, Organovo's shares have ranged in value from as little as $0.1933 up to $13.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organovo's is 0.9459. This would suggest that Organovo's shares are less volatile than average (for this exchange).
Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.